The purpose of this application is to demonstrate the capability of The Ohio State University AIDS Clinical Trials Unit's virology laboratory to function as one of the core Virology Laboratories for the ACTU network. This ACTG laboratory will perform the protocol virologic monitoring as mandated by the ACTG protocols and Virology Core Committee. These include HIV antigen testing, HIV cultures and the measurement and evaluation of other viral markers as diagnostic methods evolve. Participation in quality assurance programs will standardize and validate assay results. Prior experience in the performance of a large number of these assays and the maintenance of a high level of proficiency and quality control for the last three years attests to the capability of this laboratory to perform this work. The OSU ACTU virology laboratory was/is not primarily organized as a basic research laboratory doing experimental studies ut as a clinical laboratory developing standardized assays. This concept is most important in performing the protocol mandated virologic assays where the goal is providing consistently accurate results using a consensus assay on a large number of specimens. Laboratory certifications from a variety of organizations attests to achieving this goal. Nevertheless the laboratory still has performed well in the application and development of virologic assays in the clinical setting and currently participates in the on-going evaluation of new quantitative virologic culture techniques. In addition, the virology facilities were recently constructed and were built with an expansion in function expected. Thus, both space and equipment are ample to safely handle the expected increase in specimen load.

Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Brashers, Dale E; Basinger, Erin D; Rintamaki, Lance S et al. (2017) Taking Control: The Efficacy and Durability of a Peer-Led Uncertainty Management Intervention for People Recently Diagnosed With HIV. Health Commun 32:11-21
Peterson, Jennifer L; Rintamaki, Lance S; Brashers, Dale E et al. (2012) The forms and functions of peer social support for people living with HIV. J Assoc Nurses AIDS Care 23:294-305
Winham, Stacey J; Slater, Andrew J; Motsinger-Reif, Alison A (2010) A comparison of internal validation techniques for multifactor dimensionality reduction. BMC Bioinformatics 11:394
Raboud, Janet M; Diong, Christina; Carr, Andrew et al. (2010) A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy. HIV Clin Trials 11:39-50
Williams, Pl; Wu, Jw; Cohn, Se et al. (2009) Improvement in lipid profiles over 6 years of follow-up in adults with AIDS and immune reconstitution. HIV Med 10:290-301
Skowron, Gail; Spritzler, John G; Weidler, Jodi et al. (2009) Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr 50:250-8
Sax, Paul E; Tierney, Camlin; Collier, Ann C et al. (2009) Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 361:2230-40
Ma, Qing; Forrest, Alan; Rosenkranz, Susan L et al. (2008) Pharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers. Biopharm Drug Dispos 29:91-101
Collier, Ann C; Tierney, Camlin; Downey, Gerald F et al. (2008) Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV. HIV Clin Trials 9:91-102
Demeter, Lisa M; DeGruttola, Victor; Lustgarten, Stephanie et al. (2008) Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials 9:11-25

Showing the most recent 10 out of 97 publications